Conferences

Assessing Tab-Cel for EBV+ Post-Transplant Lymphoproliferative Disease

November 17th 2021

AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed data from the ALLELE study to be presented at ASH 2021.

FDA Grants RMAT Designation to ALLO-715 for Relapsed/Refractory Multiple Myeloma

April 21st 2021

The FDA granted a Regenerative Medicine Advanced Therapy designation to the allogeneic chimeric antigen receptor T-cell therapy as a potential treatment for patients with relapsed/refractory multiple myeloma.

CAR T-Cell Therapy Makes a Splash in MCL, But Optimal Sequencing Remains an Open Question

April 20th 2021

The FDA approval of brexucabtagene autoleucel established CAR T-cell therapy as a treatment option for patients with relapsed/refractory mantle cell lymphoma.

Dr. Neelapu on Emerging CAR T-Cell Therapies in Relapsed/Refractory MCL

February 24th 2021

Sattva Neelapu, MD, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma.

Deepu Madduri, MD, on the Design of the Phase 1b/2 CARTITUDE-1 Trial

January 12th 2021

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.

FDA Approval Sought for Cilta-Cel in Relapsed/Refractory Multiple Myeloma

December 21st 2020

December 21, 2020 - A rolling submission of the biologics license application for the BCMA-directed CAR T-cell product ciltacabtagene autoleucel for use in adults with relapsed/refractory multiple myeloma has been initiated to the FDA.

Negrin Shines Light on the Orca-T Story in GVHD

December 7th 2020

What started out as a journey to better understand regulatory T cells has now led to an intriguing approach with an investigational cell therapy designed to prevent the risk of graft-versus-host disease and to improve relapse-free survival rates in patients undergoing hematopoietic stem cell transplantation.

Christian Buske, MD, on the Influence of CAR T-Cells Being Presented at ASH

December 7th 2020

The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.

ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma

December 7th 2020

An off-the-shelf CAR T-cell therapy that targets B-cell maturation antigen, ALLO-715, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

Ide-Cel Delivers Clinically Meaningful HRQoL Benefits in Triple-Class Exposed Relapsed/Refractory Myeloma

December 6th 2020

Treatment with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel was found to yield clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.